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ABSTRACT 
Objectives: The aims of this study were to determine the effects of increas- 
ing doses of gliclazide on postprandial glucose excursions after a standardized 
breakfast and lunch, and to clarify the relationship between gliclazide dose and 
glucose response. 
Methods: This prospective, open-label, case-controlled, dose-escalation 
study was conducted at the Addington Hospital Diabetes Clinic, eThekwini/ 
Durban, KwaZulu-Natal, South Africa. Male and female patients aged ___18 years 
with type 2 diabetes mellitus (DM) and postprandial hyperglycemia (2-hour 
postprandial blood glucose [PPBG 2 h] level, ___11.1 mmol/L [___200 mg/dL]) and 
receiving an oral hypoglycemic agent were eligible. After a 1-week washout 
period during which patients were asked to discontinue treatment with all oral 
hypoglycemic agents, baseline glycemic measurements were performed (fast- 
ing blood glucose, PPBG 2 h, 6-hour postprandial blood glucose [PPBG 6 h], mean 
blood glucose [MBG], plasma insulin, fasting serum fructosamine, and glycosyl- 
ated hemoglobin). All patients ubsequently received 2 weeks of oral treatment 
with each of 3 doses of gliclazide: 40, 80, and 160 mg/d. Glycemic parameters 
were measured at the end of each dosing interval. Adverse-effect monitoring 
included direct reporting of untoward effects to the resident medical practi- 
tioner, clinical examination, monitoring of home blood glucose records, hema- 
tology, and liver and kidney function tests. Compliance was assessed using pill 
counts, examination of diary entries, and patient interview. 
Results: Thirty-three patients were screened; 14 entered the dose-escalation 
phase. Thirteen patients completed the study (7 women, 6 men; mean [SD] age, 
52.0 [11.1] years); 1 was withdrawn because of poor compliance. Dose escala- 
tion from 40 to 80 mg/d was associated with a significant change only in MBG 
(mean [SD], 11.3 [4.2] vs 10.0 [3.9] mmol/L [203.6 (75.7) vs 180.1 (70.3) mg/dL]; 
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P < 0.001). Dose escalation from 80 to 160 mg/d was associated with a signifi- 
cant change only in PPBG 6 h (9.5 [4.2] vs 10.3 [4.1] mmol/L [171.1 (75.7)vs 185.6 
(73.9) mg/dL]; P = 0.018). No other significant changes in glycemic parameters 
between doses were found throughout the treatment period. No adverse ffects 
were reported. 
Conclusions: In this small study of gliclazide dose escalation in patients 
with type 2 DM and postprandial hyperglycemia, gliclazide 80 mg/d was associ- 
ated with a reduction in postprandial hyperglycemia. Dose escalation from 80 
to 160 mg/d was not found to be associated with additional clinical benefit. 
Based on these results, we recommend that gliclazide dose escalation to the 
maximum dose recommended by the manufacturer be guided by measures of 
glycemia. All doses were well tolerated. (Curr TherRes Clin Exp. 2006;67:81-102) 
Copyright © 2006 Excerpta Medica, Inc. 
Key words: type 2 diabetes mellitus, oral antidiabetic agents, oral hypo- 
glycemic agents, gliclazide, postprandial hyperglycemia, sulfonylureas. 
INTRODUCTION 
The Diabetes Control and Complications Trial 1 and the United Kingdom Pro- 
spective Diabetes Study 2found the benefits of blood glucose control in types 1 
and 2 diabetes mellitus (DM), respectively. The findings of these landmark stud- 
ies have since entrenched glucose levels as a surrogate biochemical marker to 
predict clinical outcomes in patients with type 1 or 2 DM. 
Following the findings of those 2 trials, clinicians have focused the manage- 
ment of DM on the regulation of blood glucose (ie, attaining near-normoglycemia 
[fasting blood glucose (FBG) level, 4.0-6.0 mmol/L (72.1-108.1 mg/dL)]). Clini- 
cians commonly base the pharmacotherapy of hyperglycemia on the objective 
parameters of FBG, fructosamine, and glycosylated hemoglobin (HbAlc). 
However, increasing evidence supports and emphasizes the importance of 
targeting postprandial hyperglycemia (2-hour postprandial blood glucose 
[PPBG2 h] level, 2 hours after a meal, _ 11.1 mmol/L [___200 mg/dL]). 3Postprandial 
blood glucose (PPBG) levels have been reported to be better predictors of 
glycemic ontrol and to correlate better with HbAlc compared with FBG. 4 In a 
review of literature concerning elevated PPBG as a risk factor for cardiovascu- 
lar disease in patients with type 2 DM, Bonora and Muggeo 5 concluded that 
postprandial hyperglycemia, even in the absence of fasting hyperglycemia, was 
a risk factor for ischemic heart disease. In a prospective, randomized, con- 
trolled study of blood glucose monitoring in pregnant women with type 1 DM 
in northern Ireland, Manderson et al 6 found that PPBG monitoring and regula- 
tion were associated with a significantly reduced prevalence of preeclampsia 
compared with preprandial blood glucose monitoring and regulation (3% vs 
21%; P < 0.048). Furthermore, in a prospective, randomized study of combina- 
tion treatment with short-acting (regular) plus intermediate-acting (NPH) human 
insulin in 66 patients with gestational DM in the United States, de Veciana et al 7 
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found that PPBG monitoring and regulation were associated with improved out- 
comes in pregnancy (mean [SD] birth weight, 3469 [668] vs 3848 [434] g). 
Sulfonylureas (SUs) are a well-established class of drugs used for the man- 
agement of type 2 DM. They are also the most commonly used first-line oral 
antidiabetic agents. 8 One second-generation SU, gliclazide, is a well-established 
oral hypoglycemic agent used in the management of type 2 DM. Gliclazide, 
like all SUs, promotes insulin secretion by closing adenosine triphosphate- 
sensitive potassium channels in the pancreatic [3-cell membrane, resulting in 
opening of voltage-dependent calcium channels and subsequently increasing 
intracellular Ca 2+, which induces phosphorylation of proteins, which in turn 
stimulate insulin release. 9,1° The dose-response r lationship of gliclazide has 
not been firmly established. Nonetheless, gliclazide is extensively used in 
South Africa. 
The epidemiologic evidence supporting PPBG monitoring and regulation and 
the dose-response r lationships ofSUs11--gliclazide 12 in particular--motivated 
the present study. The aims of this study were to determine the effects of 
increasing doses of gliclazide on postprandial glucose excursions after a stan- 
dardized breakfast and lunch, and to clarify the relationship between gliclazide 
dose and glucose response. 
PATIENTS AND METHODS 
This prospective, open-label, case-controlled, ose-escalation study was con- 
ducted at the Addington Hospital Diabetes Clinic, a tertiary referral hospital in 
eThekwini/Durban, KwaZulu-Natal, South Africa. The study protocol was ap- 
proved by the ethics committee at the University of Durban-Westville, South 
Africa. Permission to conduct he study at Addington Hospital was obtained 
from the KwaZulu-Natal Department of Health and the manager of Addington 
Hospital. The study was conducted in accordance with the Declaration of 
Helsinki and its amendments 13 and the Patients' Rights Charter. 14 All patients 
provided written informed consent o participate. 
Inclusion and Exclusion Criteria 
Male and female patients were identified using the medical records of the clinic; 
those meeting the inclusion criteria and consenting to participate in the study 
were enrolled. Patients were not compensated for their participation. Inclusion 
criteria were as follows: age, ___18 years; type 2 DM (duration, ---6 months); current 
treatment with an oral hypoglycemic agent; capillary FBG level, 8 to 10 mmol/L 
(144-180 mg/dL); HbAlc concentration, 8% to 10%; and postprandial hyper- 
glycemia (PPBG 2 h, ---11.1 mmol/L [___200 mg/dL]). 
Exclusion criteria were as follows: significant renal impairment (serum crea- 
tine level, >1.8 mg/dL); impaired liver function (alanine aminotransferase, 
aspartate aminotransferase, total bilirubin, or alkaline phosphatase >2.5-fold 
the upper limit of normal); poor compliance, as assessed using a pill count at 
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each study visit; poorly controlled DM; current or history of alcohol or other 
drug abuse; hematologic disorder (white blood cell count, <2.0 × 109 cells/L; 
platelet count, <100 × 109 cells/L); congestive heart failure; and porphyria. 
Women who were pregnant or breastfeeding also were excluded. 
Study Drug Administration and Efficacy Assessments 
The primary efficacy end points were changes in PPBG 2 h and 6-hour PPBG 
(PPBG6 h) with dose increase. Secondary efficacy end points were changes in 
FBG level, area under the blood glucose-time curve from time 0 to 6 hours after 
breakfast (AUC0_6), and MBG level. 
The study included a screening visit (week -1), a 1-week washout period, and 
4 additional clinic visits (weeks 0 [baseline], 2, 4, and 6). Hematology (full blood 
cell count) and biochemistry (liver and kidney function tests; serum lipid lev- 
els; HbAlc; serum levels of fructosamine, creatinine, electrolytes, and CO2; urea; 
and FBG) were performed in all patients. Anthropomorphic measurements 
(height, weight, and waist and hip circumferences) also were determined. Full 
body examinations, including vital sign measurements, were performed by the 
resident medical practitioner (M.L.). Also at the screening visit, eligible patients 
were asked to discontinue all t reatment with oral hypoglycemic agents for 
1 week (washout period) and throughout the study. Treatment with other con- 
comitant medications was continued and itemized throughout the study. Pa- 
tients received instructions from a nurse on using a home glucose monitor 
(Glucostix, Ames Division, Miles Laboratories, Elkhart, Indiana) and were asked 
to record their FBG levels each day on waking in a patient diary during the 
washout period. Patients received counseling on appropriate diet from the resi- 
dent dietician, and were asked to record and report any major changes in 
dietary or exercise habits throughout the study. 
One week after screening (week 0; baseline), patients returned to the clinic after 
an overnight fast, and a blood sample was drawn to determine fasting levels of 
serum fructosamine, plasma insulin, and blood glucose. A standardized breakfast 
was then administered, followed by a standardized lunch 4 hours later. The 
researcher (P.N.) observed the complete consumption of the meals, which 
occurred within -10 minutes. To determine AUC0~, blood glucose levels were 
measured at 30-minute intervals for 6 hours after breakfast; hese measurements 
included PPBG 2 h and PPBG 6 h" Plasma insulin was measured again 30 minutes after 
breakfast. At the end of the baseline visit, patients were supplied with gliclazide 
80-mg tablets, to be self-administered at 40 mg (1/2 tablet) QD in the morning with 
a meal and -250 mL water for 2 weeks, commencing the following morning. 
At week 2, patients returned to the clinic after an overnight fast and received 
gliclazide 40 mg 15 minutes before a standardized breakfast was administered. 
A standardized lunch was administered 4 hours after breakfast. Blood glucose 
was measured at 30-minute intervals for 6 hours after breakfast; hese measure- 
ments included PPBG 2 h and PPBG 6 h" Fructosamine and insulin were measured 
as during the baseline visit. At the end of the week-2 visit, patients were asked 
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to begin self-administering a dose of 80 mg QD for 2 weeks, beginning on the fol- 
lowing morning. 
Measurements at week 4 were performed as during week 2; the gliclazide 
dose was increased to 160 mg QD. Measurements atweek 6 (study end) were 
performed as during screening (hematology, biochemistry, anthropomorphic 
measurements, and full body examination) and fructosamine, insulin, and glu- 
cose were measured as at weeks 2 and 4. On completion of the study, all 
patients were reintegrated into the diabetes clinic (ie, resumed their usual oral 
hypoglycemic agent reatment). Figure 1 and Table I provide a synopsis of the 
study procedures and the assessments conducted at each visit, respectively. 
Based on recommendations from the American Diabetes Association 
(ADA)) 5 acceptable clinical control of postprandial hyperglycemia was defined as 
a PPBG 2 h level 8 to 10 mmol/L (144-180 mg/dL). The proportion of patients who 
1 -Week interval 
Week-1 • Screening 
Week 0: Baseline assessments 
2-Week interval 
Week 2: Gliclazide 40 mg/d assessments 
2-Week interval 
Week 4: Gliclazide 80 mg/d assessments 
2-Week interval 
Week 6: Gliclazide 160 mg/d assessments 
Patients reintegrated into diabetes clinic 
Figure 1. Study procedure. 
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Table I. Out l ine  of  s tudy  assessments. 
Week 2 Week 4 Week 6 
Week-1  Week 0 (Gliclazide (Gliclazide (Gliclazide 
Assessment (Screening) (Baseline) 40 mg/d)  80 mg/d)  160 mg/d)  
Hemato logy  U - - - U 
Liver function tests ~ - - - 
Kidney function tests ~ - - - 
Serum lipid levels U - - - U 
HbAlc U - - - U 
Fasting serum fructosamine ~ ~ ~ ~ 
Serum creatinine ~ - - - 
Urea ~ - - - 
Electrolytes and CO 2 , /  - - - , /  
FBG U U - U U 
Anthropometr ic  measures ~ - - - 
Full body  examinat ion U - - - U 
FPI - U U U U 
Blood glucose q 30 min for 6 h - U U U U 
Blood insulin 30 min after 
standardized breakfast - ~ ~ ~ 
PPBG - U U U U 
Adverse effects - - ~ ~ 
U = Assessment performed; - = assessment not performed; HbA lc = glycosylated hemoglobin; FBG = fast- 
ing blood glucose; FPI = fasting plasma insulin; PPBG = postprandial blood glucose. 
achieved acceptable control of postprandial hyperglycemia was determined at 
each study visit. 
Patients were withdrawn from the study if they withdrew their consent, expe- 
rienced signs and/or symptoms of hypoglycemia, nd/or had a blood glucose 
level <3.2 mmol/L (<57.6 mg/dL) at any stage of the study. 
Laboratory Analysis 
All liver and kidney function tests and glycemic measurements were per- 
formed at the laboratory at Addington Hospital. Blood sampling was carried out 
by the resident physician as per hospital protocol. Approximately 10 mL of 
blood was drawn for each sample. At the clinic, blood glucose was measured 
using a glucose meter (Accucheck Active, Roche Diagnostics, Mannheim, 
Germany). The finger-prick method provided rapid (-5 seconds) results and 
allowed for early detection of extremes in blood glucose levels and institution of 
remedial measures. The accuracy of the results of the finger-prick test were con- 
firmed using standard laboratory analysis of PPBG 2 h" Insulin levels were deter- 
mined using an insulin electrochemiluminescence immunoassay kit (Elecsys 
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Systems D-68298, Roche Diagnostics). Analysis of HbAlc was carried out using 
the Cobas Integra method (Roche Diagnostics, Inc., Somerville, New Jersey). 
Anthropometric Measures 
Height was measured using a stadiometer, and weight was obtained using a 
standard electronic digital scale. Waist circumference was obtained at the level 
of the umbilicus, and hip circumference was measured at the maximum circum- 
ference around the hips. This methodology was similar to that adopted by 
Tulloch-Reid et al. 16 
Glucose Profiles 
MBG was determined as follows: 
MBG = [(Sum of glucose levels during the 6-hour assessment period 
for patient l /n) + (Sum of glucose levels for patient 2/n) .../N] 
where n = the number of glucose measurements during the 6-hour study period, 
and N = total number of patients. 
Surrogate Measures of Insulin Resistance and Insulin Secretion 
The homeostat ic model assessment (HOMA)-2 calculator software (Univer- 
sity of Oxford, Oxford, United Kingdom) was used to determine HOMA-IR, 
which is a surrogate marker of insulin resistance (IR) and was used to describe 
the IR status of the study cohort.  Patients with HOMA-IR values >1.57 were 
classified as insulin resistant. Acute insulin release (AIR) was calculated as the 
difference in insulin levels at 30 and 0 minutes, and served as a surrogate 
marker of first-phase insulin secretion. Response was defined as HOMA-IR ___1 
and any increase in AIR. The rate of response was determined at study end. 
Tolerability Assessment 
Adverse-effect monitoring included direct reporting of untoward effects to 
the resident medical practit ioner (M.L.), clinical examination, monitoring of 
home blood glucose records, hematology, and liver and kidney function tests. 
Compliance Assessment 
Compliance was assessed using pill counts, examination of diary entries, and 
patient interview. Compliance was enforced using telephone calls to the pa- 
tients each day. 
Statistical Analysis 
A sample size of 11 patients was required to detect a difference of 2 mmol/L 
(36 mg/dL) between any two levels of glucose, with a probabil ity of 0.05 and 
80% power, assuming a constant SD of 3.22 mmol/L (58 mg/dL) at each dose 
interval. Buoen et a117 assessed cohort  size in Phase I dose-escalation trials and 
concluded that a sample size of ___10 patients was sufficient. 
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Continuous variables are expressed as mean (SD) unless otherwise stated. 
The paired samples t test was used to determine differences between continu- 
ous variables at 95% CI. Statistical significance was assumed for P values <0.05. 
Data collection and statistical analysis were performed using SPSS version 11.5 
(SPSS Inc., Chicago, Illinois). 
RESULTS 
Study Population 
Of the 33 patients who were screened, 14 satisfied the inclusion criteria and 
were enrolled in the study. Thirteen patients completed the study (7 women, 
6 men; mean [SD] age, 52.0 [11.1] years). One patient was withdrawn because 
of poor compliance. Seven patients not currently receiving antihypertensive 
treatment did not reach the ADA 15 optimal blood pressure of <130/80 mm Hg. 
In 11 (84.6%) patients, the duration of DM was between 0 and 5 years. 
All 13 patients had hyperlipidemia (low-density lipoprotein cholesterol level, 
>3.9 mmol/L; total cholesterol level, >5.9 mmol/L; triglyceride l vel, >1.84 mmol/L). 
Eleven patients were categorized as obese based on World Health Organization 
criteria (body mass index, ->30 kg/m2). 18 On entry, 9 (69.2%) patients had IR. 
However, 12 patients had elevated globulin levels (mean [SD] in patients with 
elevated globulin levels, 36 [4] g/L [normal range, 20-32 g/L]). The hematologic 
parameters were within the normal ranges at baseline and at the completion of 
the study in all 13 patients. The demographic characteristics and baseline bio- 
chemistry and hematology of the study cohort on entry are presented in Table II 
and Table III, respectively. 
Efficacy 
Table IV shows the glycemic measurements found in the study population. 
Mean levels of PPBG 2 h and PPBG 6 h at each dose of gliclazide are depicted in 
Figures 2 and 3, respectively, and Table IV. The change from baseline in mean 
PPBG2 h was not statistically significant with gliclazide 40 mg/d. Mean (SD) 
PPBG2 h was significantly reduced from baseline with doses of 80 and 160 mg/d 
(from 12.5 [4.6] to 10.1 [4.4] and 10.5 [4.1] mmol/L, respectively [from 225.2 
[82.9] to 181.9 [79.3] and 189.2 [73.9] mg/dL, respectively]; P = 0.005 and P = 
0.011, respectively). Mean PPBG 2 h did not change significantly with dose esca- 
lation from 80 to 160 mg/d (Figure 2 and Table IV). 
Mean (SD) PPBG 6 h was significantly reduced from baseline with all 3 doses of 
gliclazide (40, 80, and 160 mg/d) (from 13.9 [4.3] to 10.1 [3.8], 9.5 [4.2], and 10.3 
[4.1] mmol/L, respectively [from 250.4 [77.5] to 181.9 [68.5], 171.1 [75.7], and 185.6 
[73.9] mg/dL, respectively]; P = 0.001, P = 0.001, and P = 0.005, respectively). The dif- 
ference in mean PPBG 6 h Was not significantly different between the 40- and 80-mg/d 
doses. However, there was a statistically significant decrease in mean PPBG 6 h when 
the gliclazide dose was increased from 80 to 160 mg/d (P = 0.018) (Figure 3 and 
Table IV). 
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Table II. Demographic characteristics of study patients 
(N  = 13). 
Characteristic Value 
Age, y 
Mean (SD) 52.0 (11.1) 
Range 37-77  
95% CI 46-58 
Sex, no. (%) 
Female 7 (53.8) 
Male 6 (46.2) 
Race, no. (%)* 
Asian 9 (69.2) 
Black 2 (15.4) 
White 1 (7.7) 
Mixed 1 (7.7) 
Disease duration, no. (%) 
0-<5 y 11 (84.6) 
5-<10 y 1 (7.7) 
_>1o 1 (7.7) 
Weight, kg 
Mean (SD) 82.4 (18.1 ) 
Range 48.5-116.0 
95% CI 72.6-92.2 
Height, cm 
Mean (SD) 167 (10) 
Range 155-182 
95% CI 162-1 72 
BMI (kg/m 2) 
Mean (SD) 29.48 (5.87) 
Range 18.70-41.10 
95% CI 26.29-32.67 
Waist/hip ratio (all patients) 
Mean (SD) 1.0 (0.1) 
Range 0.9-1.2 
95% CI 9.9-1.1 
Waist circumference, cm, mean (SD) 
Women 106 (17) 
Men 96 (12) 
Received OHAs before washout, no. (%) 
Metformin 5 (38.5) 
Glibenclamicle 8 (61.5) 
BMI = body mass index; OHA = oral hypoglycemic agent. 
*Percentages do not total 100% due to rounding. 
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Table IV. Glycemic measures at baseline (week 0) and throughout  he treatment period 
in patients receiving gliclazide for postprandial hyperglycemia (N = 13). a Val- 
ues are mean (SD). 
Week 0 Week 2 Week 4 Week 6 
Parameter (Baseline) (40 mg/d) (80 mg/d) (160 mg/d) 
PPBG2 h , mmol/L 12.5 (4.6) 12.5 (4.2) 10.1 (4.4) b 10.5 (4.1) c 
PPBG6 h , mmol/L 13.9 (4.3) 10.1 (3.8) a 9.5 (4.2) a 10.3 (4.1) b,e 
FBG, mmol/L 11.6 (3.2) 1 1.8 (3.7) 9.6 (2.9) f 9.8 (3.5)9 
AUC0_6, mmol .  h/L 76.3 (22.4) 67.7 (21.4) h 59.9 (20.8) i,j 61.0 (20.9) i
MBG, mmol/L 12.7 (4.2) 11.3 (4.2) k 1 0.0 (3.9)J ,k 1 0.2 (3.9) k 
PPBG2 h = postprandial (2 h) blood glucose; PPBG 6 h = postprandial (6 h) blood glucose; FBG = fast- 
ing plasma glucose; AUC0~ = area under the blood glucose-time curve from 0 to 6 hours after admin- 
istration of standardized breakfast; MBG = mean blood glucose. 
aTo convert to conventional units, 19 divide by 0.05551; bp = 0.005 versus baseline; cp = 0.011 versus 
baseline; dp = 0.001 versus baseline; ep = 0.018 versus 80 mg; fP = 0.028 versus baseline; gP = 0.035 
versus baseline; hp = 0.029 versus baseline; ip = 0.003 versus baseline; ip ~ 0.001 versus 40 mg; kp 
0.001 versus baseline. 
18-  
16-  
--- 14-  
m 
o 12-  
E 
E 
v 10-  
8 -  
O 6 -  
4 -  
2-  
0 I I I I 
Week 0 Week 2 Week 4 Week 6 
(Baseline) (40 mg/d)  (80 mg/d)  (160 mg/d)  
Figure 2. Mean (SD) 2-hour postprandial blood glucose (PPBG 2 h) levels at baseline 
(week 0) and throughout  the t reatment  period in patients receiving glic- 
lazide for postprandial hyperglycemia (N = 13). *P = 0.005 versus baseline; 
tp = 0.011 versus baseline. 
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(Baseline) (40 mg/d) (80 mg/d) (160 mg/d) 
Figure 3. Mean (SD) 6-hour postprandial blood glucose (PPBG 6 h) levels at baseline 
(week 0) and throughout the treatment period in patients receiving glic- 
lazide for postprandial hyperglycemia (N = 13). *P = 0.001 versus baseline; 
tp = 0.005 versus baseline; *P = 0.018 versus 80 mg. 
Nine (69.2%) patients achieved acceptable clinical control of postprandial 
hyperglycemia at the 80-mg/d ose. Dose escalation from 80 to 160 mg/d did not 
increase the number of patients achieving target PPBG levels. 
Figure 4 and Table IV show the changes in mean FBG with dose. Mean FBG 
was not significantly reduced from baseline with the 40-mg/d ose of gliclazide. 
However, the mean FBG concentration was significantly reduced from baseline 
with the 80- and 160-mg/d oses of gliclazide (from 11.6 [3.2] to 9.6 [2.9] and 9.8 
[3.5] mmol/L, respectively [from 209.0 [57.6] to 172.9 [52.2] and 176.5 [63.1] mg/dL, 
respectively]; P = 0.028 and P = 0.035, respectively). There was no significant dif- 
ference in mean FBG between the 80- and 160-mg/d oses of gliclazide. Figure 4 
shows the "plateau effect" on FBG as the dose of gliclazide reaches 160 mg/d. 
Figure 5 depicts the blood glucose-time profiles throughout the study. The 80- 
and 160-mg/d oses of gliclazide appeared to be associated with similar glucose 
profiles, suggesting a minimal difference between these 2 doses when the blood 
glucose-time profiles are used as the pharmacodynamic arker (plateau effect). 
The AUC0_ 6 values at each dose are shown in Figure 6. Mean (SD) AUC0_ 6 val- 
ues were significantly reduced from baseline at the 40-, 80-, and 160-mg/d oses 
of gliclazide (from 76.3 [22.4] to 67.7 [21.4], 59.9 [20.8], and 61.0 [20.9] mmol. h/L, 
respectively [from 1374.5 (403.5) to 1219.6 (385.5), 1079.1 (374.7), and 1098.9 
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Figure 4. Mean (SD) fasting blood glucose (FBG) levels at baseline (week O) and 
throughout the treatment period in patients receiving gliclazide for post- 
prandial hyperglycemia (N = 13). *P = 0.028 versus baseline; tp = 0.035 ver- 
sus baseline. 
(376.5) mg. h/dL, respectively]; P= 0.029, P= 0.003, and P= 0.003, respectively). 
There was a progressive reduction in the mean AUC0_ 6 value as the dose of 
gliclazide was increased from 40 to 80 mg/d (P < 0.001). However, the difference 
between the 80- and 160-mg/d oses was nonsignificant. 
Mean (SD) MBG concentrations were significantly reduced from baseline 
with gliclazide 40, 80, and 160 mg/d (from 12.7 [4.2] to 11.3 [4.2], 10.0 [3.9], and 
10.2 [3.9] mmol/L, respectively [from 228.8 (75.7) to 203.6 (75.7), 180.1 (70.3), and 
183.8 (70.3) mg/dL, respectively]; all, P < 0.001) (Figure 7 and Table IV). The re- 
duction in mean MBG concentration was statistically significant when gliclazide 
was increased from 40 to 80 mg/d (P < 0.001). However, the difference in mean 
MBG concentrations between the doses of 80 and 160 mg/d was nonsignificant. 
The AUC0_ 6 and MBG values were consistent with those of the full glucose- 
time profiles. No significant differences in HbAlc were found (Figure 8). 
Surrogate Measures of Insulin Resistance and Insulin Secretion 
On entry, 2 of 11 (18.1%) patients with available data had insulin sensitivity 
as defined on HOMA-IR (Table IV). The number of patients with insulin sensitiv- 
ity was not altered with gliclazide administration; 2 (18.1%) patients were insu- 
lin sensitive on completion of the study. 
The numbers of patients with a significant increase from baseline in AIR 
seemed similar with gliclazide 40 and 80 mg/d (7 and 8 patients, respectively) 
(Table V). However, dose escalation from 80 to 160 mg/d resulted in 4 (30.8%) pa- 
tients showing an apparent decrease in AIR. 
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Figure 5. Mean blood glucose excursions versus time profiles at baseline (week 0) 
and throughout the treatment period in patients receiving gliclazide for 
postprandial hyperglycemia (N = 13). 
To lerab i l i ty  
None of the patients reported or were found to have any adverse ffects. 
DISCUSSION 
The high prevalences of IR, obesity, hyperlipidemia, nd hyperglycemia at base- 
line in this study suggest hat the cohort had features characteristic of the 
metabolic syndrome. 
The maximum percentage r ductions in PPBG 2 h and PPBG 6 h--19% and 32%, 
respectively--were similar to those reported in previous studies (range, 
18%-25%). 20-24 The minimum dose at which the greatest number of patients (9 
[69.2%]) achieved acceptable clinical control of postprandial hyperglycemia 
was 80 mg/d, emphasizing that patients hould undergo a trial of SUs (eg, glic- 
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Figure 6. Mean (SD) area under the blood glucose-time curve from time 0 to 6 hours 
after study drug administration (AUC0_6) at baseline (week 0) and through- 
out the treatment period in patients receiving gliclazide for postprandial 
hyperglycemia (N = 13). *P = 0.029 versus baseline; tp = 0.003 versus base- 
line; ~P ~ 0.001 versus 40 mg. 
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Figure 7. Mean (SD) mean blood glucose (MBG) levels at baseline (week 0) and 
throughout the treatment period in patients receiving gliclazide for post- 
prandial hyperglycemia (N = 13). *P = 0.001 versus baseline; tp ~ 0.001 versus 
40 mg. 
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Figure 8. Mean (SD) glycosylated hemoglobin (HbAlc) concentrations before and 
after treatment in patients receiving gliclazide for postprandial hyper- 
glycemia (N = 13). 
lazide) before newer agents specifically targeting postprandial hyperglyce- 
mia (meglitinides, ~-glucosidase inhibitors, rapid-acting insulin analogs) are em- 
ployed. The fact that the mean PPBG 2 h value did not change significantly with 
dose escalation from 80 to 160 mg/d suggests that gliclazide 160 mg does not 
offer any additional benefit in reducing PPBG 2 h compared with 80 mg/d. 
Furthermore, the significant increase in mean PPBG 6 h from 80 to 160 mg/d (P = 
0.018) suggests a deterioration of glycemic ontrol. 
Mean FBG was reduced from baseline by 17% and 16% with gliclazide 80 and 
160 mg/d, respectively. These reductions appear similar to those reported by 
Brogard et al, 25 Guillausseau, 2° Sinay et al, 23 and Wing et a126 (21.7%, 26.7%, 
23.8%, and 28.6%, respectively). 
FBG is dependent on endogenous glucose production, which, in turn, is 
dependent on IR and basal insulin secretion. 27First-phase insulin secretion has 
been associated with suppression of endogenous glucose production after 
ingestion of a meal. 28 The loss of first-phase insulin secretion is an important 
defect in type 2 DM and results in postprandial hyperglycemia. In the present 
study, AIR served as a surrogate marker of first-phase insulin secretion. 
Gliclazide 160 mg/d seemed to be associated with impaired AIR, suggesting that 
it reduced first-phase insulin release. The finding that gliclazide did not improve 
the prevalence of IR, but improved insulin secretion, in this study population 
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Table V. Response* at baseline (week O) and throughout the treatment period in pa- 
tients receiving gliclazide for postprandial hyperglycemia (N = 13). 
Week 0 Week 2 Week 4 Week 6 
Parameter (Baseline) (40 mg/d) (80 mg/d) (160 mg/d) 
No. (%) of patients 
with IR defined as 
increased AIR 
No. (%) of patients 
with IR as determined 
using HOMA-IR 
7/10 (70.0) 8/10 (80.0) 4/10 (40.0) 
2/11 (18.2) 0/11 (0) 1/13 (7.7) 2/13 (15.4) 
IR = insulin resistance; AIR = acute insulin release; HOMA-IR = homeostatic model assessment-insulin 
resistance. 
*Response was defined as follows: HOMA-IR -<1 and any AIR increase compared with baseline. 
suggests that gliclazide has a limited effect on insulin sensitivity and that the 
effect of gliclazide on FBG might be related to basal insulin secretion. 
The association of gliclazide with reduced FBG and PPBG levels might result in 
an option for glycemic ontrol if these effects can be maintained in the long term 
(-10 years). However, this ideal is unlikely to be achieved because DM is charac- 
terized by a progressive decline in pancreatic function, 29,3° which would necessi- 
tate combination therapy with insulin sensitizers (eg, biguanides) and/or insulin. 31 
The high prevalence of IR in this study cohort (18.1%) further supports the use of 
combination therapy, particularly with insulin sensitizers. Traditionally, pharma- 
cotherapy for type 2 DM has been aimed at improving lycemic ontrol, with or 
without correcting IR. 32 In view of the increasing evidence indicating the central 
role of IR in hypertension, hyperlipidemia, obesity, dysfibrinolysis, and hyper- 
uricemia, the use of SU monotherapy might not be rational because, although it
might result in acceptable clinical control of postprandial hyperglycemia ini- 
tially, it theoretically would not correct he IR that might be present. Because IR 
is a central feature of the metabolic syndrome, which was prevalent in the pres- 
ent study cohort, the possible failure of gliclazide to effectively improve IR is 
concerning. 
The mean PPBG 2 h, FBG, AUC0_6, and MBG values were similar at the 80- and 
160-mg/d oses, suggesting that dose increments >80 mg/d might not be clini- 
cally beneficial (ie, plateau effect). Assessment of the clinical response of the 
patients found that the proportions of patients who attained acceptable clinical 
control of postprandial hyperglycemia at 80 and 160 mg/d were similar (69.2% 
with both doses). However, 1 (7.7%) patient achieved acceptable control at the 
160-mg/d ose but not at the 80-mg/d ose, suggesting that a subset of patients 
might be more responsive to higher doses (eg, 160 mg/d) of gliclazide. This 
responsiveness of patients to the relatively high dose of gliclazide has been 
observed with other SUs. 33 Briefly, some subjects responded (ie, achieved FBG 
4-6 mmol/L) with glibenclamide 20 mg/d and not 10 mg/d. 
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The finding of no significant differences in HbAlc was expected ue to the 
short duration of the study (7 weeks). HbAlc typically is used for detecting 
changes in glycemia over an 8-to 12-week period. 
The plateau effect of gliclazide (and other SUs) with dose escalation has been 
reported previously. 31,33-35 A clinical study of gliclazide in patients with type 2 DM 
conducted by Shaw et a112 found that increasing the dose of gliclazide from 
80 to 160 mg/d during long-term administration might not increase antihyper- 
glycemic activity. Rambiritch, 33in a dose-escalation study of glibenclamide 5,
10, 15, and 20 mg/d in 22 patients with type 2 DM in South Africa, found a lack 
of added glycemic control with doses of glibenclamide >5 to 10 mg/d (mean 
[SD] FBG levels at doses of 10 and 20 mg/d, 11.5 [3.84] and 11.2 [4.15] mmol/L, 
respectively; P = 0.782). This finding supports the observation by Jonsson et 
a134 that maximal therapeutic efficacy of glibenclamide occurred within the 
dose range of 7.0 mg/d (median HbAI~, 7.2% [range, 6.3%-10.3%]) to 10.5 mg/d 
(median HbAI~, 8.0% [range, 6.0%-9.9%]) in a prospective study in 50 pa- 
tients with type 2 DM in Sweden. The results of the present study agree with 
the growing consensus that maximal reductions in glycemia are found with 
SU doses approximately half the manufacturers' maximum recommended daily 
dose.31,35 
This study found a statistically significant increase in PPBG 6 h (e  = 0.018), 
indicating a decrease in glycemic control, when the dose of gliclazide was 
increased from 80 to 160 mg/d. The maximum manufacturer's ecommended 
dose 1° of 320 mg/d was not used in this study. Therefore, it is speculative as to 
what effect the higher dose of gliclazide would have had. If the trend toward 
reduced glycemic ontrol with doses >80 mg/d were to continue, then higher 
doses would have produced a paradoxical increase in blood glucose levels. 
However, based on a MEDLINE search for literature concerning liclazide (key 
terms: gliclazide, dose escalation, and efficacy; years: 1970-2005), no studies 
have found a deterioration of glycemic control with high doses of gliclazide. 
Nonetheless, this phenomenon has been described for other SUs (eg, glipizide 36,37 
and glibenclamide33,38). Dose escalation from 80 to 160 mg/d was associated 
with an apparent reduction in AIR, which might explain the apparent deteriora- 
tion in glycemic control. However, the reason for high-dose SUs impairing 
glycemic control requires elucidation. It is tempting to speculate that this 
impairment might be due to the SU-induced hyperinsulinemia, which conse- 
quently would increase appetite and food intake, leading to glucotoxicity, 
although, based on our literature search, no published ata are available. In a 
prospective study of glibenclamide in 15 patients with type 2 DM in South Africa 
by Jackson and Robertson, 38this increase in appetite and food intake was 
described as patients "eating to keep up with their glibenclamide dose." 
Because the doses of many pharmacologic agents in diverse drug classes 
have been altered from those recommended by the manufacturer, 39 we recom- 
mend that the efficacy and tolerability of less-than-recommended doses of SUs 
be reviewed through postmarketing surveillance. 4° 
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Study Limitations 
The generalizability of the findings of the present study is limited because this 
study was of a short  duration (7 weeks) and the sample size was small (n = 13). 
Gliclazide was not escalated to the maximum manufacturer 's  recommended 
dose of 320 mg/d because of the potential danger of hypoglycemia and because 
this dose is not commonly  prescr ibed in clinical pract ice in South Africa. 
Although no adverse effects of gliclazide were found or reported,  the small sam- 
ple size might have limited their detection. 
CONCLUSIONS 
In this s tudy of gliclazide dose escalation in patients with type 2 DM and post- 
prandial hyperglycemia, gliclazide 80 mg/d effectively reduced postprandial  
hyperglycemia. Dose escalation from 80 to 160 mg/d was not found to be clini- 
cally beneficial with regard to postprandial  hyperglycemia. Based on these 
results, we recommend that gliclazide dose escalation to the maximum dose 
recommended by the manufacturer  be guided by measures of glycemia. 
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